Harvard Bioscience Secures $40M Loan Agreement

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialHarvard Bioscience ( (HBIO) ) has provided an update. On December 17, 2025, Harvard Bioscience finalized a $40 million loan agreement with BroadOak Capital Partners to refinance its existing debt, improve liquidity, and strengthen its financial structure. The financing package includes three term loans with varying repayment and conversion terms, aimed at enhancing the company’s operational flexibility and stability. This agreement also grants BroadOak board representation, with Partner Bill Snider joining Harvard Bioscience’s board, alongside the establishment of a scientific advisory board to guide strategic opportunities. These developments mark a significant step in the company’s long-term growth and operational positioning within the life sciences sector. The most recent analyst rating on (HBIO) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page. Spark’s Take on HBIO Stock According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral. Harvard Bioscience’s overall stock score reflects significant financial challenges and valuation concerns, partially offset by positive technical indicators and operational improvements highlighted in the earnings call. The appointment of a new board member adds a slight positive outlook. To see Spark’s full report on HBIO stock, click here. More about Harvard Bioscience Harvard Bioscience, Inc. specializes in developing, manufacturing, and distributing technologies, products, and services that enable breakthroughs in life science applications, including research, drug discovery, bio-production, and preclinical testing. Serving top-tier academic institutions, government laboratories, and leading pharmaceutical and biotechnology companies, it operates globally in markets such as the U.S., Europe, and China through direct and distribution channels. Average Trading Volume: 6,276,066 Technical Sentiment Signal: Sell Current Market Cap: $31.21M Find detailed analytics on HBIO stock on TipRanks’ Stock Analysis page.